CON: maintenance is not cost-effective

L. Horvath (Sydney, Australia)

Source: Annual Congress 2012 - Pro/Con Debate "Cost-effectiveness of maintenance chemotherapy for NSCLC"
Disease area: Thoracic oncology

Slide presentationMultimedia files

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Horvath (Sydney, Australia). CON: maintenance is not cost-effective. Annual Congress 2012 - Pro/Con Debate "Cost-effectiveness of maintenance chemotherapy for NSCLC"

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
PRO: maintenance is cost-effective
Source: Annual Congress 2012 - Pro/Con Debate "Cost-effectiveness of maintenance chemotherapy for NSCLC"
Year: 2012


Fluticasone/salmeterol combination (FSC) is safe and provides effective long-term (52 week) control in the management of patients with persistent asthma (PA)
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001

Asthma control: which tools are feasible in primary care?
Source: Annual Congress 2013 –Primary Care Programme "Asthma management in clinical practice"
Year: 2013


CON
Source: Annual Congress 2004 - Controversies in the management of acute pulmonary thromboembolism
Year: 2004

Four-month regimens: are they feasible?
Source: International Congress 2015 – Tuberculosis: short-course chemotherapy
Year: 2015



Budesonide/formoterol with an adjustable maintenance plan costs less, and is as effective as fixed dosing
Source: Eur Respir J 2002; 20: Suppl. 38, 397s
Year: 2002

Aiming for total control of asthma with salmeterol/fluticasone propionate (SFC), a cost effective option
Source: Eur Respir J 2005; 26: Suppl. 49, 430s
Year: 2005

Improvement in asthma control and reduction in medical resource use following treatment with montelukast (PRAACTICAL Study)
Source: Eur Respir J 2005; 26: Suppl. 49, 576s
Year: 2005

Budesonide/formoterol maintenance and reliever therapy for asthma in general practice: is it cost-effective?
Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care
Year: 2008

Are mobile device applications effective at supporting COPD self-management compared to usual care?
Source: International Congress 2019 – M-health/e-health II
Year: 2019


Overall asthma control with budesonide/formoterol maintenance and relief vs conventional best practice
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008

Quality control: a necessary, but sometimes overlooked, tool for improving respiratory medicine
Source: Eur Respir J 2009; 33: 722-723
Year: 2009


Adjustable maintenance dosing (AMD) with budesonide/formoterol (B/F) meets guideline-defined management goals more effectively than fixed dosing (FD) with B/F or salmeterol/fluticasone (S/FL)
Source: Eur Respir J 2004; 24: Suppl. 48, 311s
Year: 2004

Physical therapy continuous monitoring in ICU in a large public hospital: an effective strategy to optimize the weaning process in critical patients
Source: Annual Congress 2007 - Critical care and airways clearance
Year: 2007


Are disease management programs for COPD cost-effective?
Source: Annual Congress 2012 - Effectiveness of respiratory disease management in primary care
Year: 2012